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Environmental and occupational exposures of 
pregnant women may lead to negative health 
effects ranging from low birth weight to 
developmental defects in the baby (Buczynska 
and Tarkowski 2005). In some cases, long-
term effects, such as diabetes and chronic 
heart disease, are postulated to have their basis 
in fetal and early childhood exposure and 
development (Barker et al. 2002). Therefore, 
an understanding of fetal responses to envi-
ronmental exposures is of increasing impor-
tance. If exposures occurred close to birth, 
and/or if the exposures are to substances with 
long half-lives that persist as a body burden 
through pregnancies, direct measurement of 
environmental agents in umbilical cord blood 
can be useful. However, because we are often 
most interested in effects of labile stressors at 
earlier stages in pregnancy (during organogen-
esis), the temporal aspect of toxic assault may 
best be dealt with by identifying biomarkers 
of effect that can indicate enduring biological 
changes that suggest both historical exposures 
throughout gestation and potential future 
adverse health outcomes. 
Inhaled cigarette smoke is a common and 
high-quantity environmental exposure involv-
ing a complex mixture of multiple toxic sub-
stances, including carcinogens and mutagens. 
Directly inhaled mainstream cigarette smoke 
contains > 4,000 compounds (Rodgman et al. 
2000). The relationship between smoking 
and poor health is well established (Armour 
et al. 2005; Keys et al. 2004), as are the health 
effects in neonates of mothers who smoke 
during pregnancy (Beratis et al. 1999; Bjørke 
Monsen et al. 2004; Department of Health 
and Human Services 2004). Because 10.7% 
of women in the United States smoke during 
pregnancy (Martin et al. 2005), the at-risk 
population of about 420,000 newborn infants 
each year is relatively high in the United 
States and, of course, much higher globally. 
Documented negative impacts on the fetus 
resulting from maternal cigarette smoking 
include preterm delivery and shortened gesta-
tion, fetal growth restriction and low birth 
weight, and sudden infant death syndrome 
(Department of Health and Human Services 
2004). Other less well established adverse 
effects include later increased risk of type II 
diabetes, obesity, asthma, and impaired cog-
nitive development (DiFranza et al. 2004; 
Gilliland et al. 2001; Montgomery and 
Ekbom 2002; Von Kries et al. 2002). Whereas 
cotinine in umbilical cord blood is a useful 
indicator for exposure to maternal active and 
passive smoking (Pichini et al. 2000), in utero 
biomarkers of toxic effects from cigarette 
smoke are still lacking.
Although genetic methods represent a 
relatively straightforward tool of testing for 
heritable diseases and susceptibility, protein 
biomarkers appear particularly well suited for 
measuring and detecting phenotypic mani-
festations of exposure and disease. For epi-
demiologic studies and clinical applications, 
proteomic mining strategies for biomarker 
discovery have focused on blood serum and 
plasma, because this compartment is rela-
tively accessible and potentially provides a 
host of diagnostic information (Lathrop et al. 
2003). Mass spectrometry (MS) is at the 
forefront of proteomic technologies for the 
global analysis of complex specimens such 
as human serum, which displays a high and 
thus challenging dynamic range with respect 
to protein abundance (Aebersold and Mann 
2003; Anderson and Anderson 2002). This 
challenge is typically addressed by using pre-
fractionation steps (e.g., depletion, precipi-
tation, and strong cation exchange) before 
mass spectrometric analysis for enhancing the 
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Ba c k g r o u n d: Exposures of pregnant women to natural and manmade chemicals can lead to 
  negative health effects in the baby, ranging from low birth weight to developmental defects. In some 
cases, diseases were postulated to have their basis in toxic exposure in utero or in early childhood. 
Therefore, an understanding of fetal responses to environmental exposures is essential. To that end, 
cord blood is a readily accessible biofluid whose proteomic makeup remains mostly unexplored 
when compared with that of adults.
oBjectives: Our goal was an initial global assessment of the fetal serum proteome and for the identifi-
cation of protein biomarkers indicative of toxic in utero exposures related to maternal cigarette smoking.
Me t h o d s : Drawing from a repository of 300 samples, we selected umbilical cord blood sera from 
12 babies born to six smokers and six nonsmokers and analyzed both sample pools by tandem mass 
spectrometry in conjunction with isobaric tags (iTRAQ) for protein quantification.
re s u l t s: We identified 203 proteins, 17 of which were differentially expressed between the cigarette 
smoke–exposed and control populations. Most of the identified candidate biomarkers were biologically 
plausible, thereby underscoring the feasibility of screening neonates with global proteomic techniques 
for biomarkers of exposure and early biological effects triggered by in utero chemical exposures.
co n c l u s i o n s: This validation study provides an initial view of the proteome of human cord blood 
sera; it demonstrates the feasibility of identifying therein by use of proteomics, biomarkers of envi-
ronmental, toxic exposures. 
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range of proteins detected (Li et al. 2005). 
Furthermore, isobaric tags for relative and 
absolute quantitation (iTRAQ) reagents (Ross 
et al. 2004) make it possible to quantita-
tively screen the entire proteome within the 
detectable dynamic range for qualitative and 
quantitative differences in protein expression 
between individuals and groups differing in 
exposure history, health status and disease.
Here we describe the application of quanti-
tative tandem mass spectrometry (MS/MS) for 
the global, nontargeted characterization of the 
fetal cord blood serum proteome—an impor-
tant task that has not yet been documented 
in the peer-reviewed literature. Our goal was 
to screen neonates for candidate biomarkers 
indicative of early biological responses to toxic 
exposures from smoke constituents in utero. 
Once obtained, an initial “snapshot” of pro-
teins expressed in umbilical cord blood serum 
may serve as the starting point for developing 
low-cost assays for biomarkers of exposure and 
disease in this easily accessible and presumably 
information rich biofluid. 
Methods
Sample selection and collection. Samples were 
collected from a subset of all singleton births 
that occurred from November 2004 to March 
2005 at the Johns Hopkins Hospital, Baltimore, 
Maryland. This study required the collection 
of specimens that otherwise would have been 
discarded, and used information from medi-
cal records that was available to hospital per-
sonnel. The study received a HIPAA (Health 
Insurance Portability and Accountability Act) 
waiver. There was no requirement for informed 
consent because all samples and data were 
anonymous. All experimental protocols were 
approved by the Johns Hopkins Medicine 
Institutional Review Board (IRB) before sample 
collection under IRB approval number 04-04-
22-02. A total of 341 samples were collected, 
of which 300 met information and volume cri-
teria for the larger study. Human umbilical 
cord serum samples were collected immediately 
after birth using the Witter cord cradle (Witter 
et al. 2001), and stored at 4°C for < 3 hr before 
further processing. Serum samples were centri-
fuged at 1,000 × g for 15 min in a bench top 
centrifuge (Fisher Scientific, Palo Alto, CA). 
Aliquots were placed at –80°C for long-term 
storage. Measurement of cotinine was con-
ducted as previously described (Bernert et al. 
1997). Briefly, after sample extraction prepa-
ration, we analyzed serum using positive-ion 
atmospheric pressure chemical ionization MS/
MS.We identified cotinine by multiple reaction 
monitoring of the characteristic mass transition, 
m/z 177 → 80, compared with a deuterated 
internal standard. In addition, we abstracted 
data from medical charts of mothers and infants 
relevant to smoking, birth outcomes, and health 
problems during pregnancy, labor, and delivery 
(Table 1). 
From the abstracted data, we identified 
a subset of six infants of self-reported mater-
nal smokers whose smoking status was veri-
fied by umbilical serum cotinine levels of 
> 10 ng/mL (representing active smokers) 
and six controls, identified as infants of self-
reported nonsmokers with cotinine levels of 
less than the detection limit of 0.015 ng/mL. 
Self-reported nonsmokers with cotinine levels 
above the limit of detection were excluded 
from this study. All selected infants were term 
(≥ 37 weeks by obstetrical estimate) African-
American males born by normal spontaneous 
vaginal delivery and having no known preex-
isting health conditions of parent and/or child, 
no known recreational and prescription drug 
use, and no acute infection of the mother, 
as noted on the records abstracted from the 
medical chart, and sufficient serum for analy-
sis (complete cohort information is available 
online; THREE Study 2008).
Protein purification and depletion. Stored 
serum (–80°C) was thawed to room tempera-
ture and aliquots of 100 µL were removed for 
processing. Samples were diluted to 500 µL 
using phosphate-buffered saline (PBS). The 
diluted samples were filtered through a 
0.22-µm Spin-X filter (Sigma Chemical Co., 
St. Louis, MO) at 3,000 × g for 30 sec. A 
100-µL sample was applied onto a ProteoPrep 
Top 20 protein immunoaffinity column 
(Sigma), which had previously been washed 
and equilibrated using PBS. Samples were 
incubated at room temperature for approxi-
mately 30 min, and then centrifuged at 2,000 
× g for 30 sec to elute the depleted proteins. 
Immunoaffinity columns were washed with 
PBS twice, and these fractions were pooled 
with the initial flow-through, resulting in a 
pool of ~ 1.5–2 mL for each subject; each pool 
was concentrated to approximately 100 µL 
using Ultrafree MC 5 kDa molecular weight 
cutoff filters (Sigma). Bound proteins (the 
“top 20 proteins,” not used in this study) were 
eluted per the manufacturer’s directions to 
recharge the columns. Columns were then 
washed, re-equilibrated, and reused for mul-
tiple samples. We determined protein concen-
trations at each step using the bicinchoninic 
acid (BCA) assay (Pierce Biotechnology, 
Rockford, IL) to assess protein depletions. We 
assayed success of depletion (~ 98%) of major 
proteins by visualizing less abundant ones on 
silver-stained gels (data not shown).
SDS-PAGE. During all steps, we assessed 
sample quality and reproducibility by sodium 
docecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE) using 4–12% Tris-HCl 
gels (Bio-Rad, Hercules, CA). Protein samples 
(approximately 2 µg) were run at 150 V for 
~ 1 hr in 1X Tris-glycine-SDS buffer (BioRad) 
using the BioRad mini-Protean vertical electro-
phoresis system. Staining was completed using 
a published silver stain protocol (Shevchenko 
Table 1. Characteristics of nonsmoking and smoking mothers and their babies.
  Apgar score
Subject  Gravida  Marital status  Age (years)  Education (years)  Alcohol   1 min  5 min  Birth weight (g)  Cotinine (ng/mL)  Gestational age (days)
Nonsmokers 
  1  5  Single  29  11  No  9  9  4,044  0.0075a  287
  2  2  Married  29  > 16  No  9  9  3,719  0.0075  280
  3  3  Single  24  16  No  7  9  2,824  0.0075  286
  4  2  Single  25  12  No  8  9  2,824  0.015  282
  5  5  Single  38  12  No  9  9  3,199  0.0075  275
  6  9  Single  28  10  No  9  9  3,851  0.0075  273
  Mean  4  Single  29  13  No  9  9  3,410  0.0088  281
Smokers 
  7  6  Single  27  12  No  9  9  2,919  125  279
  8  4  Married  39  14  Missing  8  9  3,289  143  270
  9  11  Married  36  12  No  9  9  3,566  368  269
  10  7  Single  22  10  No  9  9  3,580  118  285
  11  5  Married  33  15  No  4  6  2,050  229  272
  12  2  Single  18  10  No  8  9  2,529  150  271
  Mean  6  Single  29  12  No  8  9  2,989  189  274
No statistically significant differences were observed (p > 0.05). There was a trend for nonsmokers to have, on average, a 6-day longer gestational age (p = 0.053) and to be an average 
of 421 g heavier (p = 0.12). 
aAssuming 1/2 limit of detection.Colquhoun et al.
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et al. 1996), and gels were imaged at 500 dpi 
using a Umax PowerLook 3 scanner with 
MagicScan software (version 4.5; Techville, 
Inc., Dallas, TX).
Protein digestion and iTRAQ labeling. 
Before analysis, two pools were formed by 
combining the sera of babies born to smokers 
and those of babies born to nonsmoking moth-
ers. Pooled samples were prepared in dupli-
cate, thereby producing a total of 4 samples 
(2 + 2), each containing approximately 100 µg 
of protein (smoker pool and nonsmoker pool). 
These four pools were subjected to precipita-
tion using 10% trichloroacetic acid in acetone 
(–20°C, overnight) followed by an acetone 
wash (–20°C, 15 min) and resuspension in 
20 µL of 0.5 M triethyl ammonium bicarbon-
ate. Duplicate composite samples of exposed 
and controls were subjected to iTRAQ label-
ing to produce technical replicates.
The pooled smokers and nonsmokers 
purified and depleted serum proteomes were 
reduced at 60°C for 1 hr with 2 µL 50 mM 
tris(2-carboxyethyl)phosphine (TCEP), 
and subsequently alkylated using 200 mM 
s-methyl methane thiosulfonate (MMTS) 
(1 µL) for 10 min. After digestion overnight 
at 37°C using 10 µL of 0.5 µg/µL porcine 
trypsin (Promega, Madison, WI), iTRAQ 
labeling was conducted for 1 hr at room tem-
perature (Ross et al. 2004). The contents were 
then combined into a single tube and reduced 
to a volume of 50 µL. 
Strong cation exchange (SCX) chromato-
graphy. Chromatography by SCX was carried 
out using a PolyLC polysulfoethyl A column 
(10 cm, 2.1 mm, 5 µM particles, 300 Å pore) 
at a flow rate of 250 µL/min. We collected 
22 fractions using a Probot fraction collec-
tor (Dionex, Sunnyvale, CA) along a 40-min 
gradient of 10 mM potassium phosphate in 
20% acetonitrile and 350 mM potassium 
chloride in 10 mM potassium phosphate in 
20% acetonitrile.
LC-MS/MS analysis. After an initial 
survey of the cord serum proteome in non-
depleted samples using nanospray liquid 
chromatography (LC) MS/MS, we performed 
all further analyses on SCX-fractionated pro-
teomes using the same method. Briefly, pep-
tides (5 µL) were separated on a C18 75-µM 
column hand packed with YMC ODS-AQ 
(5 µM particle, 120 Å pore size) in 0.1% for-
mic acid on a gradient (5–40%) using 0.1% 
formic acid/ 90% acetonitrile in 60 min, and 
a second, steeper gradient from 40–90% in 
5 min. The flow rate was 300 nL/min. We 
conducted MS using an Applied Biosystems 
Q-Star Pulsar with a spray voltage of 2.2 kV 
(Applied Biosystems, Foster City, CA). We 
conducted a survey scan at m/z 350–1,200 
and obtained subsequent data-dependent 
MS/MS scans for the three most intense ions 
using a 30-sec exclusion window. Data were 
analyzed using Protein Pilot, and mass spec-
tra searched against the Swiss-Prot database 
release 52.5 (iTRAQ quantitative data) and 
Mascot database revision 070518 (nonquan-
titative; 4937571 sequences and 1702359384 
residues) (Pappin et al. 1993) to determine 
log confidence scores for protein identifica-
tion and to generate iTRAQ ratios (Applied 
Biosystems 2006). We validated the iTRAQ 
labeling by searching the data against the 
Swiss-Prot database using Mascot selecting 
iTRAQ modification as a variable modifica-
tion. Quantitative data were exported from 
ProteinPilot to Excel (Microsoft, Bellevue, 
WA) and 95% confidence intervals (CIs) 
were generated for each ratio comparison 
(m/z 114:115, 114:116, 114:117; 115:114, 
115:116, and 116:117). Each pairwise com-
parison was subjected to a two-tailed t-test 
to determine whether the ratio was different 
from 1 (p < 0.05). Only those proteins dem-
onstrating significant (p < 0.05) quantitative 
differences in all four pairwise comparisons 
were considered to be regulated in response to 
maternal cigarette smoke exposure. Pairwise 
comparisons of the technical replicates 
resulted in the exclusion of statistically sig-
nificant changes observed in only one tech-
nical replicate. The calculated p-values were 
exported into Q-value, and a false positive 
rate was estimated following the program’s 
instructions (Storey and Tibshirani 2003). 
Proteins matching cytokeratin were removed 
from the analysis because they were identi-
fied as laboratory contaminants based upon 
iTRAQ quantitative ratios.
Western hybridization. Five milligrams 
each of samples were electrophoretically sepa-
rated on a 4–12% NuPAGE gel. Thereafter, 
proteins were transferred to nitrocellulose 
Figure 1. Gene ontology (GO) assignments for fetal proteins identified in cord blood sera. Proteins were 
grouped by molecular function (A) and biological processes (B). Use of the GOSt tool (Gene Group 
Functional Profiling 2008) resulted in the assignment of none, a single, or multiple molecular functions and 
biological processes for each protein examined. AA, antioxidant activity; B, binding; ERA, enzyme regula-
tor activity; STA, signal transduction activity; SMA, structural molecule activity; TA, transporter activity; 
BA, biological adhesion; BR, biological regulation; CP, cellular processes; DP, development processes; 
EL, establishment of localization; ISP, immune system processes; LOCA, localization; LOCO, locomotion; 
MP, metabolic processes; MOP, multicellular organism processes; RS, responses to stimulus. Additional 
GO information and p-values can be found in the Supplemental Material, Table 3 (online at http://www. 
ehponline.org/members/2008/11816/suppl.pdf).
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Figure 2. Quantitative information for fetal proteins identified as being significantly increased or decreased 
in response to maternal smoking (p < 0.05). Candidate biomarkers were identified at the ≥ 99% confidence 
level using at least two peptides. Quantitative values were converted to log values and the 95% confi-
dence interval was calculated using pairwise comparisons between controls and smokers. Protein acces-
sion numbers, coverage information and statistical data can be found in Supplemental Material, Table 2 
(online at http://www.ehponline.org/members/2008/11816/suppl.pdf).
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filters at 50 V for 120 min in transfer buf-
fer (50 mM Tris pH 7.5, 380 mM glycine, 
0.1% SDS and 20% methanol). After block-
ing with TBS buffer (50 mM Tris, pH 7.5, 
150 mM NaCl) containing 5% nonfat pow-
dered milk (Safeway) and 0.1% Tween-20, 
filters were incubated at 4°C overnight with 
primary antibody. The following antibod-
ies were used for immunoblotting: 1:1,000 
dilution of anti-Gelsolin antibody (ab11081; 
AbCam, Cambridge, MA), which was 
selected as a control, because it showed a 
ratio equal to 1:1 in smoke-exposed and non-
exposed individuals; 1:500 dilution of anti-
α-fetoprotein (ab3980, AbCam), which was 
selected because it had a significant and high 
smoker:nonsmoker ratio. Blots were then 
washed three times (15 min each) in TBS-
Tween, incubated with 1:5,000 dilution of 
horseradish peroxidase-conjugated goat anti-
mouse or goat anti-rabbit antibodies (Pierce, 
Rockford, IL), and washed three times 
in TBS-Tween for 15 min each. Proteins 
were visualized by enhanced chemilumi-
nescence (ECL) and exposure to Hyperfilm 
MP (Amersham Biosciences, Piscataway, 
NJ). We measured quantitative data using 
ImageQuant (GE Healthcare, Piscataway, 
NJ) using digital images of scanned films. The 
pixel intensity of each individual band was 
determined and corrected using the gelsolin 
intensity for the same sample; the sum of 
smoker band intensities was compared with 
the sum of nonsmoker band intensities. We 
used an unpaired, two-tailed t-test to test for 
differences between the two conditions. 
Results
To characterize the umbilical cord proteome, 
we removed most of the most abundant 20 
proteins and carried out two-dimensional 
LC-MS/MS coupled with iTRAQ labeling 
technology (Ross et al. 2004) on the depleted 
proteome. Database searches of acquired 
mass spectra yielded 203 unique proteins 
identified with ≥ 90% confidence; 201 
of these were identified at the 95% confi-
dence level [Supplemental Material, Table 1 
(online at http://www.ehponline.org/mem-
bers/2008/11816/suppl.pdf)]. Protein cover-
age ranged from 84% for vitamin D–binding 
protein to 9.6% for immunoglobulin (Ig)
heavy chainV-I region Mot. Seventy-five per-
cent of the proteins were classified as extra-
cellular. These all had documented roles in 
binding or transport (Figure 1A). Because 
higher-order cellular processes are more var-
ied, many proteins were assigned multiple 
potential biological roles in multiple processes 
(Figure 1B). No structural or other “leakage” 
proteins were identified.
To explore proteomic changes associated 
with environmental exposures, we conducted 
additional relative quantification analyses on 
sera from babies born to smokers and non-
smokers. Representatives of both groups were 
very similar with regard to maternal gravida, 
age, education, marital status, and infants’ 
Apgar scores at 1 and 5 min. As might be 
expected, infants born to smokers were on 
average smaller and had shorter gestational 
age (see footnote in Table 1 for statistical 
information). Quantitative comparison of the 
protein expression in cord serum from infants 
of maternal smokers (average serum cotinine 
level of 187 ± 77 ng/mL) and nonsmokers 
(< 0.015 ng/mL) using a two-tailed t-test 
revealed 17 proteins whose expression was, in 
all four pairwise comparisons, statistically sig-
nificantly up- or down-regulated in response 
to maternal smoking (p < 0.05). Statistical data 
estimated using Q-value suggested a false posi-
tive rate of < 0.01 or, in this case, less than one 
protein by chance alone [See Supplemental 
Material, Figure 1 (online at http://www.
ehponline.org/members/2008/11816/suppl.
pdf)]. Most of the identified candidate bio-
markers shown in Figure 2 were abundant 
proteins. Relative abundance of proteins in 
serum from babies born to maternal smok-
ers compared with maternal nonsmokers 
ranged from 77% increases (hemoglobin 
gamma-1 subunit) to 36% decreases (comple-
ment C4-B). Some changes were relatively 
small yet statistically significant, such as those 
observed for antithrombin-III (13% decrease) 
and complement C1r subcomponent (17% 
decrease). All proteins identified in our analy-
ses were shared among babies born to smokers 
and nonsmokers; in other words, none of the 
detected proteins were unique to either study 
group. This is not surprising because these 
proteins have major structural and functional 
roles in human serum.
We identified 17 candidate biomark-
ers of toxic in utero exposure (Table 2), 14 of 
which previously had been linked to cigarette 
smoking as determined in a literature review 
(Belch et al 1984; Calori et al. 1996; Capuano 
Table 2. Candidate biomarkers found to be modulated in response to maternal smoking.
Name  Literature findings  Study 
Down-regulated in current study
  Adiponectina   Decrease observed in mice transgenic for human APOb100 in active smoking  Kim et al. 2006; Yuan et al 2007
    model, and in male smokers  
  Antithrombin-IIIa   Nonsignificant lower levels in thrombin–antithrombin complex in newborns  Mercelina-Roumans et al. 1996, 1997
    of smokers 
  Complement C1r subcomponenta   50% consumption with exposure to TGP in vivo  Koethe et al. 1995
  Complement C3a  “Significant decrease in serum C3 levels in smokers”  Capuano et al. 2006; Hsieh et al. 1984; Kew et al. 1987; 
      Koethe et al. 1995 
  Complement C4-Ba  20% consumption with exposure to tobacco glycoprotein in purified  Koethe et al. 1995
    protein studies
  Hemopexin   ND 
Up-regulated in current study
  Albumin (serum)  NR  Ahlsten et al. 1989; Ingvarsson et al 2007
  α-Fetoproteina   Significantly increased in babies of maternal smokers compared with nonsmokers  Beratis et al. 1999
  α-2-Macroglobulina   Increased in serum of smokers and of newborns of smokers. Increased in   Belch et al 1984; Goldenberg et al. 1991
    maternal smokers and associated with fetal growth retardation in their infants  
  Apolipoprotein A-Ia   Decrease by 4.2% in smokers vs. nonsmokers; decrease in infants of   Craig et al. 1989; Fager et al. 1980; Iscan et al. 1997
    smoking mothers 
  Apolipoprotein A-IV   NR  Steinmetz et al. 1988
  Fibrinogen α chaina   Significant increases in smokers and heavy smokers, but no association  Belch et al. 1984; Calori et al. 1996; Hsieh et al. 1984; 
   in newborns    van der Salm et al. 1994
  Hemoglobin α subunit  Increased hemoglobin levels in adult smokers and cord blood of smokers  D’Souza et al. 1978; Kawada 2004; Van Tiel et al. 2002
  Hemoglobin γ-1   Increased hemoglobin levels in adult smokers and cord blood of smokers  D’Souza et al. 1978; Kawada 2004; Van Tiel et al. 2002
  Hemoglobin γ-2 subunit  Increased hemoglobin levels in adult smokers and cord blood of smokers  D’Souza et al. 1978; Kawada 2004; Van Tiel et al. 2002
  Ig γ-1 chain C  Increased IgG levels in cord blood in newborns  Cervi and Feighery 1991
  Ig λ chain C  Increased IgG levels in cord blood in newborns  Cervi and Feighery 1991
Abbreviations: ND, do data found; NR, no evidence for consistent relationship to smoking. 
aProteins previously reported to vary in expression as a function of cigarette smoke.Colquhoun et al.
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et al. 2006; Cervi and Feighery 1991; Craig 
et al. 1989; D’Souza et al. 1978; Fager et al. 
1980; Goldenberg et al. 1991; Hsieh et al. 
1984; Iscan et al. 1997; Kawada 2004; Kew 
et al. 1987; Kim et al. 2006; Koethe et al. 
1995; Mercelina-Roumans et al. 1996, 1997; 
Steinmetz et al. 1988; Van Tiel et al. 2002; 
Yuan et al. 2007). Of these, 11 were previously 
described following targeted measurements in 
blood from newborns, whereas the remain-
ing ones were from experimental models (e.g., 
purified proteins, animal studies) or from 
studies of adults who had either long-term, 
high-level exposures or diseases associated 
with cigarette smoke exposure. Additionally, 
Western hybridization of samples with mono-
clonal antibodies confirmed the qualitative 
and quantitative results of the iTRAQ meas-
urements, and also produced evidence for 
significant inter-individual variability in fetal 
protein expression (Figure 3). Relative quan-
tification of α-fetoprotein by Western hybrid-
ization showed a ratio of 1:1.54 (smokers to 
nonsmokers), which was statistically significant 
(p = 0.029) and comparable to the iTRAQ 
measurements (average ratio, 1:1.4; 95% CI, 
1.31–1.5). Sample processing was performed 
with good consistency, as demonstrated by 
gelsolin measurements varying by only 6% 
between individual samples (1.012 ± 0.04). 
We identified 17 candidate biomarkers 
of exposure and effect within the fetal blood 
serum proteome. Most of these were not only 
biologically plausible but also confirmed by 
prior reports on exposure-related changes in 
their expression levels (Table 2). Detection 
of this relatively small number of modulated 
proteins (17 of 203 total; ~ 8%) demonstrates 
that the chosen methodology was sufficiently 
discriminatory and stringent. 
Discussion
Maternal smoking has been associated with 
low birth weight and other developmental 
problems, but the underlying mechanisms 
of these responses are not yet fully under-
stood. Cell metabolism interference (Hsieh 
et al. 1984), endocrine perturbation (Beratis 
et al. 1999), and hypoxia (Varvarigou et al. 
1994) have all been postulated as potential 
mechanisms for the effects of smoking-related 
health defects. Our data suggest that babies 
exposed to cigarette smoke in utero exhibit 
some individual protein expression patterns 
similar to those previously observed in adult 
smoke-exposed subjects and animal models. 
Documented effects include changes in the 
complement system (Capuano et al. 2006; 
Kew et al. 1987; Koethe et al. 1995), α-2-
macroglobulin (Belch et al 1984; Goldenberg 
et al. 1991), hemopexin and albumin (Ahlsten 
et al. 1989; Ingvarsson et al. 2007), all sugges-
tive of inflammatory alterations in the neonate. 
Alterations in Ig “C” chains are consistent with 
earlier reports that infants of smoking mothers 
have higher levels of IgG (Cervi and Feighery 
1991). Additionally detected were several 
indicators of altered lipid metabolism, specifi-
cally adiponectin (Kim et al. 2006; Yuan et al. 
2007) and two apolipoproteins, A-I and A-IV 
(Craig et al. 1989; Fager et al. 1980; Steinmetz 
et al. 1988). Interestingly, although apolipo-
protein A-I was reportedly decreased in cord 
blood of infants of smokers in a prior study, it 
was found to be up-regulated here.
There was one indicator of altered hemo-
stasis (fibrinogen). Observed changes in 
α-fetoprotein levels may be interpreted as evi-
dence for impaired fetal growth and matu-
ration, both known to be associated with 
maternal smoking (Beratis et al. 1999). 
α-Fetoprotein is produced by the fetal liver. 
In the past, its presence in cord blood has been 
associated with decreased fetal growth, a known 
consequence of maternal smoking (Beratis 
et al. 1999). Lower levels of apo  liprotein A-I 
found among infants of smoking mothers may 
indicate altered lipid metabolism (Iscan et al. 
1997), whereas increased α-2-macroglobulin 
expression points to inflammatory processes. 
The observed differential levels of hemoglobin 
subunits may well be related to a previously 
described relationship between smoking and 
higher hemoglobin levels both in adults and 
in cord blood of infants of smoking mothers 
(D’Souza et al. 1978; Kawada 2004; Van Tiel 
et al. 2002). 
The sample selection in this study was 
limited by a number of variables, first and 
foremost the availability of a sufficient quan-
tity of serum for proteomic analysis. African 
Americans were selected as the study group 
because they represented nearly 70% of the 
population sample. Other selection criteria 
were specified to remove as many effect modi-
fiers and confounding variables as possible 
(e.g., alcohol and drug use, delivery type). 
As a result of the aforementioned selection 
criteria, this study is not necessarily represen-
tative of a more diverse and heterogeneous 
population. Further studies of broader sample 
groups are required to determine whether 
the responses observed here can be general-
ized to other populations. However, the strict 
selection criteria in this study allowed for the 
identification of a number of proteins whose 
expression is changed in response to cigarette 
smoke exposure.
Global screening using the iTRAQ tech-
nique also led to the discovery and identifica-
tion of candidate biomarkers not anticipated 
or predictable a priori. The latter include the 
measured reduction of adiponectin levels in 
the pool of babies born to smoking mothers. 
This is intriguing because adiponectin has been 
implicated in metabolic syndrome in adults 
(Tajtakova et al. 2006), which may well begin 
in early childhood (Hales and Barker 2001). 
The biological role and mechanism of this and 
other incompletely understood proteins war-
rants further investigation. The construction of 
protein pathways (i.e., analyzing the results of 
proteome-wide studies by examining the rela-
tionships between regulated proteins, rather 
than on an individual protein-to-protein basis) 
may help elucidate the mechanistic basis of 
observed exposure effects, not only to cigarette 
smoke constituents but also to other environ-
mental pollutants. Furthermore, this analytical 
strategy may open novel avenues of investiga-
tion by generating physiologic hypotheses that 
later could be tested using immunoassays and 
other classical biochemical techniques. 
Overall, our work provides new evidence 
for important protein expression changes 
occurring in the fetus in response to maternal 
smoking. Although protein expression changes 
would be expected (and some of these changes 
could be unimportant or caused by various 
confounding exposures and events), the very 
fact that many of the changes observed in this 
work are either biologically plausible or previ-
ously documented in mammalian systems 
(e.g., human babies, adults, and cell culture 
lines) suggests that the results are biologically 
relevant. The utility of this proteome-wide 
approach to exploring environmental expo-
sures is that a broad screen in tandem with 
quantitative analysis can reveal a broader pic-
ture of the overall exposure effects than using 
traditional, targeted methods; however, vali-
dation and confirmation remain critical steps 
in this experimental pathway. 
Because these analyses were conducted 
on pooled samples, interindividual variability 
may be a source of uncertainty. A fairly large 
increase or decrease would be required for 
any one individual level to affect the mean 
for the pool of six individuals. We saw no 
changes in iTRAQ ratios of > 1.8:1, however. 
Sample pooling is an accepted approach in 
proteomics; its benefits and limitations have 
Figure 3. Western blot image confirming iTRAQ observed relative increases in α-fetoprotein levels in cord 
blood sera of babies born to maternal smokers versus control subjects. Gelsolin served as a reference 
protein unaffected by smoking behavior. Because sample volume was insufficient, data for the smoke-
exposed individual 7 are missing.
α-Fetoprotein
Gelsolin
3256 4189 12 10 11
Nonsmokers SmokersBiomarker detection in human cord blood proteomes
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been discussed elsewhere (Karp et al. 2005; 
Gan et al. 2007).
When working with low-volume samples, 
proteomics by necessity can achieve only lim-
ited coverage of the blood proteome, which 
contains thousands of proteins and spans a 
dynamic range of > 10 orders of magnitude 
(Anderson and Anderson 2002). Thus, the 
total spectrum of proteins contained in human 
blood certainly is much larger than what is 
reported here. Limitations are expected to arise 
from using low-volume samples and blood 
serum as opposed to plasma. Serum contains 
relatively fewer proteins but it is customarily 
collected and therefore more readily available. 
To capture low-abundance proteins such as 
interleukins, current methods require a large 
starting volume and extensive prefractionation 
for removal of more abundant proteins. Sample 
pooling can address this need when working 
with low-volume samples, such as umbili-
cal cord blood serum. The coverage achieved 
in this study is comparable to prior work, 
in which between 70 and 300 proteins were 
identified by individual MS methods (e.g., Li 
et al. 2005; Stalder et al. 2008; Whiteaker et al. 
2007). Given the low volume of serum used, 
the obtained coverage is noteworthy.
Further studies using Western hybridiza-
tion and/or high-throughput MS methods may 
represent a logical and practical next investiga-
tive step. Levels of proteins also may be scru-
tinized on a person-by-person basis to help 
understand variability among individuals. Such 
research could evaluate effects of confounders 
that were selected out of our study but which 
may be important for capturing the full range 
of protein expression. Future proteomic stud-
ies could be combined with investigations of 
genetic traits (e.g., single nucleotide polymor-
phisms) and of epigenetic changes to develop 
fundamental knowledge about the role of ciga-
rette smoke and other environmental stressors 
in adverse alterations of the phenotype.
An important yet unanswered question 
is whether the observed fetal responses to 
exposures from cigarette smoke constituents 
are enduring and indicative of deleterious 
health effects in early childhood and later in 
life. Prospective cohort studies could provide 
answers and help to further define the value 
of the umbilical cord blood serum proteome 
as a diagnostic window into human physi-
ology and pathology. Furthermore, recently 
developed high-throughput protein biomarker 
screening methods, such as multiple reaction 
monitoring, could be applied to a broader 
cohort of samples for a further validation of 
the observed biological changes (Sandhu et al. 
2008; Whiteaker et al. 2007). Because this 
method has been posited not to require abun-
dant sample preparation, a prospective cohort 
could be rapidly assayed for the absolute pres-
ence of these biomarkers.
It has been theorized that a character-
ization of neonate exposures can lead to an 
understanding of general health outcomes 
(Barker et al. 2002). Using a well-character-
ized, high-magnitude exposure, differences 
in protein abundances related to that expo-
sure were measured. This validation study 
yielded some interesting initial information 
on the composition of the human umbilical 
cord blood serum proteome and subsequent 
global measures of exposure effects upon that 
proteome. By leveraging MS technology, 
we demonstrated that the effects of environ-
mental exposures at the protein level may be 
examined in previously unforeseen ways, giv-
ing the potential to address important biologi-
cal issues from a systemwide viewpoint.
Therefore, the potential exists to expand the 
applications of high-throughput MS techniques 
for the comprehensive analysis of environmen-
tal exposures, ranging from the characterization 
of ecotoxicologic effects to the epidemiologic 
analysis of chemical exposures (Dowling and 
Sheehan 2006; Sheehan 2007). Given the pos-
itive experiences gained from this study, we 
posit that the potential for global screening for 
protein expression differences in cord blood 
repositories may aid in the investigation of 
infant health outcomes associated with in utero 
exposures to environmental toxicants. 
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